Why the Difference Between Risk and Hazard Matters for Nanotechnology
April 23, 2007
Scientific progress is a balancing act: Weigh the empirical evidence and determine the appropriate balance between allowing new technologies and protecting public health. Periodically however, development is obstructed by fear diminishing physical data. In this article, Mark Mansour discusses the idea that nanotechnology is poised to turn a bad trend of regulators, preferring to use “precautionary principles” to regulate based on means of production rather on the safety of the product, on its head and show the world that regulation based on empirical data, rather than on fear, provides the best hope for a safe future.
Copyright 2007 Small Times, PennWell Corp.
Copyright 2007 Small Times, PennWell Corp.
Related Insights
April 14, 2026
Health Care Law Today
FDA Clarifies Policies for Pharmacy Compounders of GLP-1 Products
On April 1, 2026,the U.S. Food & Drug Administration (FDA) issued a statement clarifying its compliance policy on the conditions that must be met for compounded drugs to qualify for the exemptions under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act).
April 14, 2026
Foley Career Perspectives
Trust Your Instincts: Susan Pravda on Leadership, Relationships, and Resilience
Foley partner Susan Pravda is a business lawyer focused on mergers and acquisitions, venture capital, initial public offerings, and related securities transactions and is head of Foley’s Health Care & Life Sciences Sector. She also serves as the firm’s chief strategic talent acquisition partner.
April 14, 2026
Blogs
When to Litigate and When to Walk Away
Clients faced with defending or initiating litigation often begin with the question: “Can we win?” The question sounds simple enough, and if the law is favorable, the instinctive answer might be “yes.” But “winning” in court doesn’t happen, and can’t be evaluated, in a vacuum. In reality, the odds of success in litigation depend not only on the law and facts of the case but also on any business constraints and potential consequences.